Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

tation, and 3 were EGFR wild-type.

-- All 6 patients with EGFR-activating mutations demonstrated clinical

benefit (5 PR, 1 SD).

-- XL647 is generally well tolerated in this patient population. The most

frequently reported adverse events assessed as being related to XL647

were diarrhea, rash, fatigue, and nausea, all of which were Grade 1 or

Grade 2 in severity.

"The data reported today demonstrate that XL647 has potential utility in patient populations with both mutated and wild-type EGFR," said Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University. "Importantly, the data highlight that patients to date appear to have milder EGFR-related side-effects -- rash and diarrhea -- than previously described with other EGFR inhibitors while retaining potent anti-tumor activity with durable responses and stable disease. Although these are early results, they provide a compelling rationale for expediting the full development of XL647 in non-small cell lung cancer."

"These data suggest that XL647 has the potential for utility in patients with NSCLC who have an activating EGFR mutation and those with wild-type EGFRs. We believe these data support an aggressive clinical development strategy in first, second and third-line treatment as both a single agent and in combination with other therapies," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Moreover, new data from an ongoing phase 1 trial of XL647 suggest that daily dosing results in higher drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for the late-stage development of XL647."

The most frequently reported treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and fatigue, and Grade 1 nausea and rash. Six pat
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... UAE (PRWEB) October 30, 2014 Grace Century ... Dr. James A. Manganello, Chairman of the Board, to the ... Bahamas. The appointment was made by the Ministry of ... September 24th, 2014. , More than a year ... Research Bill , Prime Minister Perry Christie said the government ...
(Date:10/30/2014)... Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... a conference call and live audio webcast on Thursday, ... its third quarter 2014 financial results. Interested ... dialing (888) 347-1165 for domestic callers or (412) 902-4276 ... live under the investor relations section of the Regado ...
(Date:10/27/2014)... Ryan Carfley , Managing Partner at Personify ... Bryan Hamilton, the publisher of the Triangle Business Journal, and ... Research Triangle region of North Carolina. , Just a few ... include the role of social media in recruitment, recruiting ... the unique role that Millennials play in the workplace today. ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... today announced two presentations demonstrating that the extent ... proprietary cancer immunotherapeutic AE37 vaccine correlated with a ... AE37 cancer vaccine is being developed by the ... ). The presentations are being made at the ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... Oncology Adjuvant Trial 9735 at 2007 San, ... Improved Overall Survival Versus ... Results presented at the,30th annual San Antonio ... early stage breast cancer who have had surgery, ...
... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
(Date:10/29/2014)... study of its kind to date, researchers have used ... the risk for autism. Joseph Buxbaum, Ph.D., Icahn School ... Daly, Ph.D., Broad Institute of Harvard and MIT, and ... affected children, parents and unrelated people. They identified changes ... the risk for autism spectrum disorder (ASD) – a ...
(Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
(Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... 02 April 2011: Thalidomide has shown potential to be used ... to data presented at the International Liver CongressTM 2011.1 ... grossly curative resection surgical removal of the cancerous ... free survival rate (65%) compared to placebo (33%). However, ...
... SPAINIrrigating agricultural crops places huge demands on water ... where agriculture is a major contributor to the ... comes from the agricultural sector. The excessive use ... concerns in Mediterranean countries, where rising demand has ...
... Ore. Engineers at Oregon State University have ... in the production of low-temperature, microchannel heat exchangers ... technology much less expensive for many commercial applications. ... researchers say, in next-generation computers, lasers, consumer electronics, ...
Cached Biology News:Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients 2Research on satellite imagery aims to advance sustainable agriculture 2Advance in microchannel manufacturing opens new industry applications 2
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
... thin foil heat sealing material is ... from a screw down heated lid), ... a useful method for sample retrieval. ... the existing seal. Ideal for compound ...
Biology Products: